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CR3The conserved region 3 (CR3) portion of the human adenovirus (HAdV) 5 E1A protein functions as a potent
transcriptional activator that induces expression of viral early genes during infection. Expression of HAdV-5
CR3 in the yeast Saccharomyces cerevisiae inhibits growth, as do the corresponding regions of the HAdV-3, 4,
9, 12 and 40 E1A proteins, which represent the remaining ﬁve HAdV subgroups. Growth inhibition is
alleviated by disruption of the SAGA transcriptional regulatory complex, suggesting that CR3 targets the yeast
SAGA complex. In yeast, transcriptional activation by several, but not all, of the CR3 regions requires the Gcn5
acetyltransferase component of SAGA. The CR3 regions of HAdV-3, 5, 9 and 40, but not HAdV-4 and 12
interact with the pCAF acetyltransferase, a mammalian ortholog of yeast Gcn5. Disruption of the previously
described N-terminal pCAF binding site abrogates binding by the HAdV-5 243R E1A protein, but not the
larger 289R E1A protein, which is otherwise identical except for the presence of CR3. RNA interference
directed against pCAF decreased HAdV-5 CR3 dependent transcriptional activation in mammalian cells. Our
results identify a second independent binding site for pCAF in E1A and suggest that it contributes to CR3
dependent transcriptional activation.© 2009 Elsevier Inc. All rights reserved.Introduction
Human adenovirus type 5 (HAdV-5) early region 1A (E1A) is the
ﬁrst viral gene to be transcribed upon viral infection. E1A binds
numerous cellular regulatory proteins and may function as a
molecular hub to reprogram gene expression and growth in the
infected cell (Pelka et al., 2008). The 13S and 12S E1A mRNAs are the
most abundant at early times during infection. They encode twomajor
products of 289 residues (R) and 243R proteins respectively, and they
share identical amino and carboxyl sequences (Fig. 1A). The only
difference between them is the presence of an additional 46 amino
acids in the larger protein that arises as the result of differential
splicing of the primary E1A transcript. This unique 46 amino acid
region and adjacent sequences is highly conserved amongst the E1A
proteins of different adenovirus serotypes, and is referred to as
conserved region 3 (CR3) (Avvakumov et al., 2002; Kimelman et al.,
1985) (Fig. 1B). CR3 contains two CXXC motifs that comprise a zinc
binding motif present in all known HAdV E1A proteins. Of the two
major E1A proteins, the larger is considered to be primarily
responsible for transcriptional activation of viral and cellular genes.tre, 790 Commissioners Road
5 8616.
ll rights reserved.This leads to the general conclusion that CR3 is critical for
transactivation by E1A. In support of this conclusion, alterations
within CR3 generally abolish E1A transactivation, whereas modiﬁca-
tions elsewhere within E1A typically have lesser effects on this
function (Glenn and Ricciardi, 1985; Lillie et al., 1986; Moran et al.,
1986a; Moran and Mathews, 1987; Moran et al., 1986b). More
persuasively, a synthetic CR3 peptide corresponding to residues
140–188 of E1A was sufﬁcient to transactivate the adenoviral E2A
promoter when microinjected into HeLa cells (Lillie et al., 1987).
E1A is able to activate transcription of many different genes that
have no obvious similarities (Liu and Green, 1994). The mechanism by
which CR3 of E1A activates transcription is complex and requires the
participation of a number of cellular factors. Detailed mutational
analyses identiﬁed a promoter targeting region embedded within CR3
that is located within residues 180–188. These residues confer
interactionwith a number of unrelated sequence speciﬁc transcription
factors (Agoff and Wu, 1994; Chatton et al., 1993; Liu and Green, 1990,
1994; Scholer et al., 1991) and several TBP associated factors (TAFs)
(Chiang and Roeder, 1995; Geisberg et al., 1995; Mazzarelli et al., 1995,
1997). TAFs function by mechanisms that are not yet well understood
as promoter selective transcriptional regulators. However, many TAFs
are known to interact with the activation surfaces of transcription
factors, and all function as components of multi-subunit protein
complexes (Green, 2000). From these results, it appears that the
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or the co-activators they recruit, results in the localization of E1A to
target promoters in the infected cell.
E1A CR3 interacts with several other factors that are critical for
transcriptional activation. The ﬁrst of these to be identiﬁed was TBP
(Lee et al., 1991) and the residues required for this interaction are
located in or around the zinc ﬁnger region of CR3 (Geisberg et al.,
1994). The second factor to be identiﬁed was the MED23/Sur2/
TRAP150β component of the Mediator/TRAP complex (Boyer et al.,
1999; Wang and Berk, 2002). Mutation of residues required for
association with MED23 abrogates transcriptional activation (Boyer
et al., 1999). More recently, we have identiﬁed p300/CBP (Pelka et al.,
2009), APIS and the 20S proteasome (Rasti et al., 2006) as factors
required for efﬁcient CR3-mediated transactivation and CtBP as a
negative regulator of CR3 function (Bruton et al., 2008). Efﬁcient
transcriptional activation by E1A CR3 relies on the co-ordination of
each of these functions, as exempliﬁed by numerous mutational,
knockdown and knockout studies (Geisberg et al., 1994; Rasti et al.,
2006; Stevens et al., 2002).
The human p300/CBPAssociated Factor (pCAF) is a transcriptional
co-activator which possesses an intrinsic histone acetyltransferase
(HAT) activity. It is a component of a large chromatin remodeling
complex and binds to the N-terminal region of E1A (Lang and Hearing,
2003; Rasti et al., 2005; Reid et al., 1998; Shuen et al., 2002). We
previously reported that pCAF, and its yeast ortholog Gcn5, also
interact with HAdV-5 E1A in vitro via a second site located within CR3
(Shuen et al., 2002). CR3 has also been shown to co-precipitate a
histone acetyltransferase (HAT) activity when expressed in yeast
(Sang et al., 2001; Shuen et al., 2002). This further suggests that this
region of E1A targets yeast Gcn5, as yeast lackp300/CBP, the only other
acetyltransferase known to bind CR3. Here we have characterized the
interaction of E1Awith pCAF in detail using bothyeast andmammalian
systems and show that pCAF contributes to transactivation by CR3.
Results
The CR3 portions of the E1A proteins from all six adenovirus subgroups
inhibit growth when expressed in yeast, which is dependent on an intact
SAGA complex
Previously, we showed that expression of the CR3 portion of HAdV-5
E1A fused to the Gal4 DNA binding domain (DBD) is sufﬁcient to inhibit
yeast growth (Shuen et al., 2002). We constructed vectors expressing
the CR3 domain of one representative E1A protein from each of the six
HAdV subgroups (Fig. 1B) and tested them for their ability to inhibit
yeast growth (Fig. 2, top row). Like HAdV-5 E1A (subgroup C), the CR3
portions of HAdV-9 (subgroup D), HAdV-4 (subgroup E), HAdV-3
(subgroup B), HAdV-12 (subgroup A) and HAdV-40 (subgroup F)
inhibited growth in the wild-type BY4741 strain yeast. Based on these
results, it appears that the CR3 portions of all the representative E1A
proteins share a common cellular target(s) conserved in yeast.
Growth inhibition mediated by the CR3 portion of HAdV-5 E1A
requires the SAGA but not the ADA yeast transcriptional activation
complex (Shuen et al., 2002). We tested the ability of the CR3 portions
of the other ﬁve subgroups to inhibit growth in yeast strains with
disruptions of GCN5, ADA3, SPT7 and AHC1 (Δgcn5, Δada3, Δspt7 and
Δahc1 respectively; Fig. 2, rows 2–5). GCN5 and ADA3 encode
components common to both the SAGA and ADA complexes. SPT7
and AHC1 encode components unique to the SAGA and ADA
complexes respectively (Eberharter et al., 1999; Lin and Vogt, 2000;
Stefanovsky et al., 2001). Like HAdV-5 CR3, the other CR3 domains did
not inhibit growth in Δada3, Δgcn5 or Δspt7 strains (Fig. 2, rows 2–4).
Growth inhibitionwas not affected by deletion of AHC1 (Fig. 2, row 5).
These results demonstrate that growth inhibitionmediated by the CR3
domains of all the E1A proteins tested depends on the presence of an
intact SAGA complex, but not the related ADA complex.The ability of different E1A CR3s to activate transcription in yeast varies
greatly, as does their dependency on the yeast SAGA complex
Studies in the simple eukaryote S. cerevisiae have shown that a
strong transcriptional activation domain can inhibit yeast growth
when tethered to the heterologous DBD (Berger et al., 1992; Shuen
et al., 2002). We reasoned that growth inhibition by the CR3 domains
of the six different E1As could be produced by a similar effect, as this
region of HAdV-5 E1A functions as a transcriptional activation domain
when fused to a DBD in mammalian cells (Bondesson et al., 1994;
Martin et al., 1990). We tested the ability of the six different CR3
regions to function as transcriptional activation domains in yeast (Fig.
3A). We co-transformed wild-type yeast and yeast with disruptions of
GCN5 or AHC1 with expression vectors for the LexA DBD or the six
different E1A CR3s fused to the LexA DBD along with pSH18-34, which
contains the LexA-responsive β-galactosidase reporter gene. The CR3
portions of the HAdV-5, 9, and 12 E1A proteins strongly activated
transcription in this system. In contrast, the HAdV-3, 4 and 40 CR3
regions were not strong activators of β-galactosidase expression.
These results indicate that there are unexpected differences in
transcriptional activation between representative CR3 regions of
each HAdV subgroup. As all CR3s inhibited growth, this phenotype
does not correlate with transcriptional activation. Thus, interaction
with SAGA is necessary for growth inhibition but is not sufﬁcient for
transcriptional activation. This is entirely consistent with the current
model of CR3 dependent activation, which requires co-ordination of
multiple cellular factors.
We next determined whether the strong transcriptional activation
observed with the HAdV-5, 9 and 12 CR3 regions was dependent on
the SAGA or ADA complexes in yeast. The ability of HAdV-9 CR3 to
activate transcription was reduced over 5 fold in the Δgcn5 strain, but
was unaffected in the Δahc1 strain. Transcriptional activation by
HAdV-5 was reduced by half in the Δgcn5 strain, but not in the Δahc1
strain. HAdV-12 CR3 differed from the other CR3s in that deletion of
GCN5 did not appreciably affect its ability to activate transcription
(Fig. 3B). These results suggest that some, but not all CR3 regions
require the SAGA complex for efﬁcient transcriptional activation.
The 289R E1A protein binds pCAF independently of the N-terminus
The observation that growth inhibition by the CR3 domains of E1A
from the six adenoviral subgroups requires an intact SAGA complex
suggests that all six of the CR3 portions of E1A interact with
components of this complex, which contains the yeast Gcn5
acetyltransferase. Numerous reports have indicated that pCAF, a
mammalian ortholog of yeast Gcn5, stably binds to the N-terminal
region of E1A (Lang and Hearing, 2003; Rasti et al., 2005; Reid et al.,
1998; Shuen et al., 2002), and we have previously shown that HAdV-5
E1A CR3 can bind pCAF and yeast Gcn5 in vitro (Shuen et al., 2002).
We tested whether CR3 could independently bind pCAF in vivo in the
context of full length E1A by co-immunoprecipitation (Fig. 4A). The
289R E1A protein co-precipitated FLAG-tagged pCAF better than the
243R E1A protein. As reported previously, incorporation of the L23A
and L24A or the L20A, L23A, L24A, I24A point mutations abrogated
binding of pCAF with the 243R E1A protein in vivo (Rasti et al., 2005).
In contrast, these point mutations did not greatly reduce the ability of
the 289R E1A protein to co-precipitate pCAF (Fig. 4A). The ability of
thesemutant 289R E1A proteins to co-precipitate substantial amounts
of pCAF suggests that, in the absence of the N-terminal binding site,
CR3 can independently interact withmammalian pCAF in vivo. Clearly,
the observed interaction with the two 289R E1A mutants is not
mediated by residual binding at the N-terminus, because the same
mutants in the 243R E1A protein do not retain any ability to associate
with pCAF (Fig. 4A).
In addition, we used a series of small deletion mutants in the
N-terminal portion of the 243R E1A protein (Mymryk et al., 1992) to
Fig. 1. Map of the major HAdV-5 proteins, positions of the conserved regions, and sequence alignment in selected portions of E1A used in this study. (A) The HAdV-5 E1A gene
encodes twomajor proteins of 289 residues (R) and 243R. The positions of the conserved regions (CR) are indicated, as are the regions reported to bind pCAF. (B) E1A CR3 fragments
used in this study and their alignment. Numbers represent the amino acid position in HAdV-5 E1A. Conserved region 3 (CR3) is indicated by the black bar. The adenovirus serotype is
indicated on the left. Darker shading denotes greater conservation. Asterisks indicate the cysteines that co-ordinate zinc.
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the N-terminus of E1A (Fig. 4B). The only mutant that completely lost
pCAF association was dl1101, which deletes residues 4–25.Fig. 2. Growth inhibition by HAdV CR3s in yeast requires the SAGA but not the ADA complex
Δada3, Δspt7, Δahc1) and the corresponding wild-type strain BY4741, were transformed
representative E1As from HAdV subgroups A–F. Transformed yeast were grown at 30 °C forWe next tested whether CR3 was sufﬁcient to confer interaction
with pCAF in the context of viral infection. HeLa cells were infected
with HAdV-5 dl1101 or dl1101/520, which is otherwise identical butes. Yeast strains containing disruptions affecting the SAGA and/or ADA complex (Δgcn5,
with an empty vector expressing the Gal4 DBD, or the Gal4 DBD fused to CR3 from
72 h and photographed.
Fig. 3. Transcriptional activation by E1A CR3 in yeast. (A) The ability of the CR3 portions
of the indicated HAdV E1A proteins to activate transcription in yeast as fusions to the
LexA DBD was tested using a β-galactosidase reporter gene construct. (B) The ability of
the indicated CR3 fusions to activate transcription was tested in yeast lacking the Gcn5
component of the SAGA complex or yeast lacking the Ahc1 component of the ADA
complex. β-galactosidase activity was measured in triplicate. Relative activation of each
CR3 region was calculated with respect to its activity in wild-type yeast.
Fig. 4. Interaction of pCAF with E1A 289R is independent of the N-terminal binding site.
(A) HeLa cells were transfected with vectors expressing FLAG-tagged pCAF and vectors
expressing genomic HAd5 E1A, E1A 243R, E1A 289R or point mutants that disrupt pCAF
binding to the N-terminal portion of E1A. Immunoprecipitations were performed using
anti-E1A antibody andwestern blotswere probedwith the anti-FLAG antibody to detect
pCAF. The input levels of the various E1A constructs and FLAG-tagged pCAF are shown in
the bottom panel. (B) Top panel: Schematic showing the various N-terminal deletion
mutants. Bottom panel: HeLa cells were transfected with vectors expressing FLAG-
tagged pCAF and vectors expressing either wild-type E1A 243R or indicated deletion
mutants of E1A 243R. Immunoprecipitations were performed using anti-E1A antibody
and western blots were probed with the anti-FLAG antibody to detect pCAF. The input
levels of the various E1A constructs and FLAG-tagged pCAF are shown in the bottom
panel.
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post-infection, the association of E1A with pCAF was determined by
co-immunoprecipitation (Fig. 5). Although the dl1101 mutation
abrogated binding of pCAF with the 243R E1A protein in the context
of infection (dl1101/520), this E1Amutation in a virus expressing both
E1A major isoforms (dl1101) retained the ability to co-precipitate
pCAF. This conﬁrms that the CR3 region of E1A can independently
confer association with pCAF during viral infection.
pCAF binding to CR3 does not require the integrity of the zinc ﬁnger
To localize the interaction of pCAFwithin the CR3 region of HAdV-5
E1A, we tested the ability of several CR3 mutants to co-immunopre-
cipitate pCAF. HeLa cells were co-transfected with vectors expressing
FLAG-tagged pCAF and wild-type HAdV-5 CR3 or selected CR3
deletion mutants fused to EGFP with a myc epitope tag (Fig. 6A).pCAF was readily co-immunoprecipitated by wild-type HAdV-5 CR3
comprised solely of residues 139–204. CR3 mutants lacking residues
161–177 bound pCAF strongly, but mutants lacking residues 139–147
or 180–188 did not (Fig. 6B). These results indicate that pCAF binding
94 P. Pelka et al. / Virology 391 (2009) 90–98requires the N-terminal and promoter targeting regions of CR3, but
not the zinc ﬁnger region. An additional experiment using the C157S
point mutant, which removes one of the Zn-co-ordinating cysteines,
retains strong interaction with pCAF (Fig. 6C).
Interaction of the six different CR3s with pCAF
We next tested whether the CR3 regions of the different
adenovirus serotypes could interact with pCAF by co-immunopreci-
pitation. We co-transfected HeLa cells with vectors expressing FLAG-
tagged pCAF and the CR3 regions of HAdV-3, 4, 5, 9, 12 and 40 fused to
EGFP with a myc epitope tag. pCAF was co-immunoprecipitated with
HAdV-3, 5, 9 and 40 CR3, but not with HAdV-4 or 12 CR3 (Fig. 7).
Knockdown of pCAF reduces transcriptional activation by HAdV-5
E1A CR3
We used a siRNA previously reported to be speciﬁc for pCAF (Bres
et al., 2002) to determine if pCAF plays a role in CR3 dependent
transcriptional activation. HeLa cells were treated with siRNA
targeting pCAF, and transfected with vectors expressing the Gal4
DBD fused to the CR3 or the N-terminal 82 amino acids of HAdV-5 E1A
and a Gal4 responsive luciferase reporter (Fig. 8A). As reported
previously (Bondesson et al., 1994; Martin et al., 1990), both these
portions of E1A activate transcription under these conditions. Knock-
down of pCAF expression reduced CR3 dependent activation by about
50%, but had no effect on activation by the N-terminal region (Fig. 8A).
Residual CR3 transactivation capacity correlated with residual pCAF
expression. A role for pCAF in HAdV-5 CR3 dependent transcriptional
activation in HeLa cells is consistent with our observation that Gcn5 is
similarly required for this protein to activate transcription in yeast
(Fig. 3B).
We further tested the effect of knocking down pCAF expression on
transcriptional activation by the CR3 regions of each of the other HAdV
subgroups in HeLa cells (Fig. 8B). Interestingly, each serotype had a
differential ability to activate transcription. As observed in yeast (Fig.
3A), HAdV-5 and 12 CR3 strongly activated transcription, whereas
HAdV-3 and 40 CR3 were very weak (Fig. 8B). In contrast to yeast,
HAdV-4 CR3 was a strong activator in HeLa cells and HAdV-9 was
completely inactive. Presumably, in these different cellular milieusFig. 5. CR3 is required for association of E1A with pCAF in the absence of N-terminal
pCAF binding domain during viral infection. HeLa cells were initially transfected with a
vector expressing FLAG-tagged pCAF and subsequently infected with either a virus
expressing the dl1101 mutant of E1A 243R (dl1101/520) or a virus expressing dl1101
mutants of both E1A isoforms (dl1101). 16 h after infection cells were harvested and
lysates were immunoprecipitated using anti-E1A antibody. Western blots were probed
with anti-FLAGmonoclonal antibody to detect pCAF or anti-E1A antibody to detect E1A.
Fig. 6. Interaction of CR3with pCAF. (A)Map of the portion of HAdV-5 E1A used in these
experiments, location of CR3 (hatched region) and relevant mutations. (B) HeLa cells
were transfected with vector expressing FLAG-tagged pCAF and wild-type HAdV-5 E1A
CR3 or the indicated deletion mutants. Immunoprecipitationwere performed using the
anti-GFP antibody andwestern blotswere probedwith the anti-FLAG antibody to detect
pCAF. The input levels of the various EGFP–CR3 constructs and FLAG-tagged pCAF are
shown in the bottom panel. (C) HeLa cells were transfected with vector expressing
FLAG-tagged pCAF and wild-type HAdV-5 E1A CR3 or the CR3 C157S point mutant.
Immunoprecipitation were performed using the anti-GFP antibody and western blots
were probed with the anti-FLAG antibody to detect pCAF. The input levels of the various
EGFP–CR3 constructs and FLAG-tagged pCAF are shown in the bottom panel.some critical interactions differ. Of the strong activators, knockdown
of pCAF did not affect HAdV-12 CR3 function, which is consistent with
our observation that activation of transcription by this protein in yeast
is similarly independent of Gcn5.
Discussion
Adenovirus E1A is a key regulator of early viral transcription and
serves as a useful model for studying eukaryotic transcription.
Multiple portions of E1A are able to alter viral and cellular
transcription. In particular, the CR3 portion of E1A has been
intensively studied as it can function autonomously as a potent
Fig. 7. Interaction of the CR3 regions of selected HAdV serotypes with pCAF. HeLa cells
were transfected with vectors expressing FLAG-tagged pCAF and the CR3 regions of
HAdV-3, 4, 5, 9, 12 or 40 E1A fused to EGFP with a myc epitope tag (see Fig. 1B).
Immunoprecipitations were performed using anti-myc antibody and western blots
were probed with an anti-FLAG antibody to detect pCAF. The input levels of the various
EGFP–CR3 constructs and FLAG-tagged pCAF are shown in the bottom panel.
Fig. 8. siRNA knockdown of pCAF reduces CR3-mediated transactivation. (A) HeLa cells
were transfected with pCAF-speciﬁc or control siRNA. Seventy-two hours after siRNA
transfections the cells were transfected with the pGal6-Luc reporter plasmid (0.5 μg)
and plasmids expressing either GAL4-DBD alone (Vector) or GAL4-DBD fused to CR3 or
the N-terminal 82 amino acids of E1A. Luciferase activity was assayed 48 h after plasmid
transfection and was normalized to protein levels. pCAF knockdown was assessed by
western blot. (B) HeLa cells were transfected with pCAF-speciﬁc or control siRNA.
Seventy-two hours after siRNA transfections the cells were transfected with the pGal6-
Luc reporter plasmid (0.5 μg) and plasmids expressing either GAL4-DBD alone (Vector)
or GAL4-DBD fused to CR3 of E1A of the indicated HAdV serotypes. Luciferase activity
was assayed 48 h after plasmid transfection and was normalized to protein levels. pCAF
knockdown was assessed by western blot.
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complex by CR3 begins with the recruitment of E1A to the template
via interaction with sequence speciﬁc DNA binding transcription
factors. CR3 subsequently orchestrates the nucleation of multiple key
transcriptional regulators, such as TBP, p300/CBP and MED23 (Boyer
and Berk, 1993; Pelka et al., 2009; Stevens et al., 2002), each of which
is required for efﬁcient activation of gene expression.
E1A is the product of a virus that infects human cells. However,
HAdV-5 E1A CR3 can also function as a transcriptional activator when
fused to a heterologous DBD in yeast, presumably due to the high
degree of conservation of some of its targets (Shuen et al., 2002).
Using a yeast model system, we have also previously shown that
HAdV-5 CR3 expression inhibits yeast growth, providing a genetic
system to identify and characterize new targets of CR3 (Shuen et al.,
2002).
We report here that the CR3 regions from six different adenoviral
subgroups inhibit growth when expressed in yeast (Fig. 2). Growth
inhibition mediated by the CR3 portions of E1A from all HAdV
subgroups requires a functional SAGA, but not ADA complex (Fig. 2).
Our results suggest that the CR3 domains from HAdV-3, 4, 5, 9, 12 and
40 share the SAGA complex as a common target, which is conserved in
yeast and in higher eukaryotic cells.
It is known that CR3 from HAdV-5 and HAdV-12 are strong
transcriptional activators when tethered to a heterologous DBD in
mammalian cells (Bondesson et al., 1994; Lipinski et al., 1997) and we
reasoned that their ability to induce gene expression could, at least to
some extent, be related to their ability to inhibit yeast growth. This is
further supported by our observation that disruption of the yeast
SAGA transcriptional activation complex reversed the growth inhibi-
tion phenotype exhibited by all six CR3s (Fig. 2). Thus, SAGA could be
exerting its effect by modulating transcriptional activation by CR3. As
observed in mammalian cells, CR3 from HAdV-5 and HAdV-12 also
functioned to activate transcription in yeast when fused to the LexA
DBD (Fig. 3A). As for the other subgroups, which to our knowledge
have never been tested for their ability to activate transcription in
either yeast or mammalian cells, only HAdV-9 E1A CR3 was able to
activate the reporter gene transcription to a level comparable to
HAdV-5 or 12 (Fig. 3A). In contrast, HAdV-3, 4 and 40 CR3 had a much
lower level of activity. Their inability to activate transcription does not
necessarily preclude them from interaction with components of the
transcriptional initiation machinery. Indeed, they simply may not
interact productively in the context of yeast to stimulate the formation
of a competent transcription pre-initiation complex. Clearly, the
interaction with SAGA is necessary for growth inhibition but is not
sufﬁcient for transcriptional activation. This is entirely consistent withthe current model of CR3 function, which requires co-ordination of
multiple cellular factors for efﬁcient transcriptional activation.
Transcriptional activation by HAdV-9 CR3was reduced by at least 5
fold in a Δgcn5 strain, whereas HAdV-5 was reduced by about 50%.
HAdV-12 CR3, which is the strongest activator in yeast, was not
reduced by a lack of Gcn5 (Fig. 3B). Thus, the dependence of the
various CR3s for Gcn5 in order to activate transcriptional varied
greatly, with HAdV-12 appearing to bewholly independent. This novel
observation suggests that the CR3 regions of individual HAdV
serotypes may function somewhat differently. In addition, the
inability of some of the CR3s to activate transcription in yeast could
be related to differential interactions with other cellular accessory
factors that are not conserved or present in yeast.
Given our observations implicating yeast Gcn5 as a target of E1A
CR3, we compared the ability of the 289R and 243R HAdV-5 E1A
proteins to associate with pCAF, a mammalian counterpart of yeast
Gcn5, via co-immunoprecipitation (Fig. 4). The 243R and presumably
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(Lang and Hearing, 2003; Rasti et al., 2005; Reid et al., 1998; Shuen
et al., 2002) and mutation of key residues in this region abrogated
pCAF binding to the 243R E1A protein. However, these same
mutations did not abrogate the ability of the 289R E1A protein to
bind pCAF. Given that the 243R and 289R E1A proteins differ only by
the presence of CR3 (Fig. 1A), we conclude that CR3 represents a
second independent pCAF binding site in E1A. This was conﬁrmed by
our observation that a portion of HAdV-5 E1A corresponding to CR3
was sufﬁcient to co-immunoprecipitate pCAF (Figs. 5 and 6) and pCAF
was immunoprecipitated from infectedHeLa cells only in the presence
of the larger 289R E1A isoform when the N-terminal pCAF binding
domain was disrupted (Fig. 5).
We also tested the individual CR3 regions from different HAdV
serotypes for binding to mammalian pCAF using co-immunoprecipi-
tation (Fig. 7). All CR3s interact with pCAF except HAdV-4 and 12.
HAdV-9 E1A CR3 appeared to bind with the highest afﬁnity. HAdV-5
E1A CR3 bound less strongly, but was still far better than the other
CR3s, such as HAdV-12. Interestingly, the effects of deleting yeast
Gcn5 in the yeast transcriptional activation assays paralleled the pCAF
binding abilities of the different E1A CR3s. Speciﬁcally, HAdV-9 E1A
CR3 was the most affected by loss of yeast Gcn5, whereas HAdV-5 E1A
CR3 was reduced by about 50% and HAdV-12 was not affected (Fig.
3B). In HeLa cells, reduction of pCAF expression by siRNA treatment
reduced activation by HAdV-5 CR3 by about 50%, and had no effect on
HAdV-12 E1A CR3 (Figs. 8A and B). Thus, the results obtained in yeast
and human cells for these two serotypes are strikingly similar. The
effect of knocking down pCAF also appeared speciﬁc to HAdV-5 E1A
CR3, as transcriptional activation by the N-terminal region of HAdV-5
E1A, a second independent transcriptional activation domain in E1A
(Bondesson et al., 1994), was not reduced (Fig. 8A). Despite binding
pCAF strongly, HAdV-9 E1ACR3was unable to activate transcription in
HeLa cells (Fig. 8B), showing that pCAF binding is not sufﬁcient to
activate transcription. Furthermore, comparative analysis of CR3-
mediated transactivation in HeLa cells showed key differences
between the CR3s of different serotypes. HAdV-5, HAdV-12 and
HAdV-4 were relatively strong transcriptional activators. Interestingly,
of these three CR3s HAdV-5 CR3 was affected the most by knockdown
of pCAF (Fig. 8B). HAdV-12 CR3 was not affected by reduction of
cellular pCAF levels, this is consistent with the observation that this
CR3 did not interact detectably with pCAF in co-immunoprecipitation
studies (Fig. 7) and agrees with our yeast results. Intriguingly, HAdV-4
CR3was a muchmore potent transactivator in HeLa cells than in yeast,
however it was not as dependent on pCAF for transactivation as HAdV-
5 CR3. This is consistent with the inability to detect pCAF association
with this CR3 in co-immunoprecipitation experiments (Fig. 7). Taken
together, our results suggest that mammalian pCAFmay serve a role in
transcriptional activation by at least some of the different E1A
proteins, and this parallels our results using yeast. Interestingly,
many viral transactivators target pCAF, including Human Papilloma
Virus E7 (Avvakumov et al., 2003), Human Immunodeﬁciency Virus-1
TAT (Kiernan et al., 1999), Foamy Virus Bel1/TAS (Bannert et al., 2004)
and Human T-cell Leukemia Virus-1 Tax (Jiang et al., 1999), suggesting
that it is utilized by many viruses to control transcription. Small
molecule inhibitors interfering with these interactions or pCAF
activity could potentially be exploited as therapeutics for controlling
diverse viral infections.
Mutational analysis (Fig. 6) indicates that pCAF binds to HAdV-5
CR3 via the less conserved residues 139–147 and the highly conserved
promoter targeting region spanning residues 180–188 (Fig. 1B).
Disruption of the zinc binding region of E1A appeared to improve
binding of pCAF with E1A (Figs. 6B and C). Perhaps the association of
other factors with this region interferes with the ability of pCAF to
bind CR3. The observed differences in pCAF binding between
serotypes (Fig. 7) are likely attributable to differences in the less
conserved N-terminal portion of CR3. This mutational analysis alsosuggests that the two ends of CR3 may come into close proximity in
the tertiary structure of CR3 to form a binding surface for pCAF.
In conclusion, our results identify a second independent binding
site for pCAF in E1A and provide the ﬁrst evidence linking the
mammalian pCAF acetyltransferase to transcriptional activation by the
CR3 portion of HAdV-5 E1A. Our results also suggest that transcrip-
tional activation by the CR3 regions of different HAdV E1A serotypes
may differ in their requirements for pCAF and other yet unidentiﬁed
factors. These observations augment our understanding of the
mechanism of transcriptional activation by this potent transcriptional
regulator and highlight the complex manipulation of host cell
processes mediated by this viral molecular hub.
Materials and methods
Plasmids and yeast strains
Yeast strain BY4741 (wild-type) and the otherwise isogenic strain
Δgcn5, Δada3, Δspt7, and Δahc1, which contain disruptions of GCN5,
ADA3, SPT7, and AHC1 respectively, were provided by Dr. Charlie
Boone (Best Institute, Toronto, ON, Canada). Yeast culture media was
prepared using standard techniques (Adams et al., 1998). The CR3
portions of HAdV-3, 4, 5, 9, 12 and 40 E1A were expressed as fusions
with the Gal4 DBD, LexA DBD or GST as described previously (Shuen
et al., 2002). These regions correspond to residues 132–209, 128–210,
139–204, 120–198, 124–210 and 117–193 of HAdV-3, 4, 5, 9, 12 and 40
E1A respectively (Fig. 1B) and were chosen based on homology with
the HAdV-5 E1A CR3 region spanning residues 139–204.
Growth suppression assay
Yeast growth suppression assays were performed as described
previously (Shuen et al., 2002). Plates were photographed 48 h post
transformation using a Foto/Eclipse Fotodyne gel doc system
(Fotodyne Inc., Hartland, WI).
β-galactosidase assays
Colonies of yeast transformed with plasmids expressing the CR3
regions of HAdV-3, 4, 5, 9, 12 and 40 fused to the LexA DBD and the
reporter plasmid pSH18-34 were picked and assayed for β-galactosi-
dase activity as described previously (Shuen et al., 2002). Enzymatic
activity was calculated as: (OD420) / (OD600× culture volume
(ml)×reaction time (minutes)) and expressed as fold activation
with respect to the vector expressing only the LexA DBD.
Mammalian expression plasmids
FLAG-tagged human pCAF was expressed from pCMX-pCAF, a
generous gift from Dr. Joe Torchia. EGFP-fusion plasmids were made
by cloning the respective E1A fragments into either pCAN-myc-EGFP
or pEGFP-C2 in frame with the N-terminal EGFP protein. E1As were
also expressed from pcDNA3.1 (Invitrogen). The genomic E1A was
expressed from pcDNA3.1 with the entire E1A gene cloned in as a
BamHI and XhoI fragment. The HAdV-5 E1A N-terminus (residues 1–
82) and CR3 were expressed as Gal4 DBD fusions using the vector pM
(Clontech).
Mammalian cell transfection
Twenty four hours prior to transfection, HeLa cells were seeded in
6-well dishes (Sarstedt) at a density of 100,000 cells per well in
DMEM. HeLa cells were transfectedwith 0.5 μg of the reporter plasmid
(pGal6-Luc) and 1.5 μg of GAL4-CR3 or GAL4-N-terminus expressing
plasmids. Transfections were carried out using the Superfect reagent
(Qiagen) according to the manufacturer's instructions.
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siRNA for pCAF was described previously (Bres et al., 2002). The
custom siRNA was ordered from Ambion and was transfected into
HeLa cells using the SilentFect transfection reagent (Bio-Rad)
according to the manufacturer's instructions. Negative control siRNA
#1 was purchased from Ambion (cat#4611). Seventy-two hours after
siRNA transfection, the cells were transfected with the indicated
plasmid mixes for luciferase assays. Luciferase activity was assayed 24
or 48 h after plasmid transfection.
Luciferase assay
Cells were collected 24 h to 72 h post-transfection and were
washed with PBS. Cells were then treated according to the protocol
provided by the manufacturer of the Steady-GLO® luciferase kit
(Promega). In brief, the washed cells were incubated with 250 μl of
lysis buffer at−80 °C. Cell extracts were collected by centrifugation at
4 °C at 14,000 g for 10 min. 50 μl of the supernatant was taken and
mixed with 50 μl of the luciferase reaction solution and the amount of
luciferase activity was measured with an EG&G Berthold Lumat
LB9507 luminometer. Luciferase activity was normalized to protein
levels.
Immunoprecipitations
For immunoprecipitation of wild-type E1A, E1A mutants or GFP–
CR3 fusions, transfected HeLa cells were lysed in high salt NP-40 lysis
buffer (0.5% NP-40, 50 mM Tris pH 7.8, 500 mM NaCl) supplemented
with protease inhibitor cocktail. One milligram of the cell lysate was
used for immunoprecipitation with the monoclonal M73 anti-E1A
antibody (Harlow et al., 1985) or anti-myc and polyclonal anti-GFP
antibody (Clontech) when EGFP–CR3 fusions were used. E1A was
detected using the M73 monoclonal antibody, while pCAF was
detected using the anti-FLAG M5 monoclonal antibody (Sigma).
EGFP–CR3 fusion proteins were detected using anti-GFP polyclonal
antibody. Associated pCAF was detected using anti-pCAF polyclonal
antibody (Sigma).
For immunoprecipitations using adenovirus infected HeLa cells,
the cells were initially transfected with FLAG-tagged pCAF expression
plasmid and subsequently infected as described below. Following a
16 h incubation period, the cells were lysed in WA lysis buffer (10 mM
Tris, pH 7.05, 50 mM NaCl, 30 mM Na4P2O7, 50 mM NaF, 5 μM ZnCl2,
10% glycerol, 0.5% Triton X-100, 1 mM Na3VO4, Sigma Protease
Inhibitor cocktail) and immunoprecipitated for 2 h using M73 anti-
E1A monoclonal antibody. Following extensive washes protein
complexes were resolved on 4–12% gradient SDS-PAGE. Associated
pCAFwas detected using anti-FLAGM5monoclonal antibody (Sigma),
E1A was detected using M73 monoclonal antibody.
Viruses and viral infections
HAdV-5 dl1101 (expressing dl1101 mutants of E1A 243R and E1A
289R) and dl1101/520 (expressing only dl1101 mutant of E1A 243R)
were applied to sub-conﬂuent HeLa cells at anm.o.i. of 10 pfu for 1 h in
serum-free media. After 1 h, complete media was added and cells
were grown for an additional 16 h prior to being harvested for co-
immunoprecipitation experiments.
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